Four other prostate cancer vaccines have reached phase III trials, namely GVAX (prostate cancer variant) containing irradiated prostate cancer cells, PPV peptide vaccine, PCVAC/PCa dendritic cell-based vaccine and PROSTVAC anti-PSA (prostate-specific antigen) vaccine [130]. This evidence concerns the gene KLK3 and prostate carcinoma.